Robert E. Davis is CSO & VP at Intra-Cellular Therapies, Inc. (ITCI). They have made 2 open-market trades across 1 company since 2017, most recently 2019-01-04.
CIK 0001291959
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITCI | 46,691 | $6.2M |
Shares reported on the most recent Form 4, priced at the 2019-01-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITCI | SELL | 2019-01-04 | 2019-01-08 | $11.41 | $187K | -1.3% | +3.2% | +4.2% |
| ITCI | SELL | 2019-01-02 | 2019-01-03 | $11.11 | $107K | +13.7% | +8.2% | +7.0% |
| ITCI | SELL · 10b5-1 | 2018-12-06 | 2018-12-07 | $13.53 | $12K | -22.0% | -16.5% | -15.4% |
| ITCI | SELL · 10b5-1 | 2018-01-04 | 2018-01-05 | $15.60 | $17K | +3.1% | -10.2% | +12.6% |
| ITCI | SELL · 10b5-1 | 2017-12-05 | 2017-12-06 | $15.00 | $10K | +6.3% | +18.7% | +52.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.